Scibase Holding
Research Scibase Holding (SCIB.ST) on Bullrun: market cap SEK 273.02M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSCIB.ST
- ExchangeSSME
- CountrySweden
- SectorHealthcare
- IndustryMedical Devices
- CurrencySEK
- Market capSEK 273.02M
- Financial periodQ1 2026
- RevenueSEK 14.28M
- Net income-SEK 24.49M
- Free cash flow-SEK 26.57M
- Gross margin49.2%
Valuation Snapshot
latest market cap is SEK 273.02M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 40.46M | -SEK 91.40M | -SEK 84.90M | 64.6% | -22.83 | SEK 22.60M | SEK 23.03M | SEK 6.66M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-16 | SEK 273.02M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 SEK.
About Scibase Holding
SciBase Holding AB (publ), a medical technology company, develops and commercializes point-of-care platforms for skin health management in Europe, the United States, North America, Asia, Oceania, and internationally. It operates through Skin Cancer and Skin Barrier Assessment segments. The company offers Nevisense and Nevisense Go point-of-care platforms to detect melanoma and non-melanoma skin cancer; and for research within skin barrier assessment.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Scibase Holding's market cap?
Scibase Holding's market capitalization is SEK 273.02M.
What does Scibase Holding do?
SciBase Holding AB (publ), a medical technology company, develops and commercializes point-of-care platforms for skin health management in Europe, the United States, North America, Asia, Oceania, and internationally. It operates through Skin Cancer and Skin Barrier Assessment segments. The company offers Nevisense and Nevisense Go point-of-care platforms to detect melanoma and non-melanoma skin cancer; and for research within skin barrier assessment.